Phase 1 Study Evaluating VT1021 in Patients With Advanced Solid Tumors

ClinicalTrials.gov ID: NCT03364400

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT03364400. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:26 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1 Study Evaluating the Safety, Pharmacology, and Preliminary Activity of VT1021 in Patients With Advanced Solid Tumors

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study is an an open-label Phase I trial of VT1021 in patients with advanced solid tumors. Patients must have recurrent or advanced cancer (i.e., solid tumors) for which standard therapy offers no curative potential.

Study identification

NCT ID: NCT03364400
Recruitment status: Not listed
Study type: Interventional
Phase: Phase 1
Lead sponsor: Vigeo Therapeutics, Inc.; Industry
Enrollment: 116 participants

Conditions and interventions

Conditions

Solid Tumor

Interventions

VT1021 Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Nov 28, 2017 (Actual)
Primary completion: Jan 2024 (Estimated)
Completion: Jun 2024 (Estimated)
Last update posted: May 15, 2023

2017 – 2024

United States locations

U.S. sites: 12
U.S. states: 8
U.S. cities: 9

Facility	City	State	ZIP	Site status
Florida Cancer Specialists	Sarasota	Florida	34232	—
Northwestern Memorial Hospital	Chicago	Illinois	60611	—
Horizon Oncology Center	Lafayette	Indiana	47905	—
The Johns Hopkins Hospital	Baltimore	Maryland	21287	—
Massachusetts General Hospital	Boston	Massachusetts	02114	—
Dana Farber Cancer Institute	Boston	Massachusetts	02115	—
Beth Israel	Boston	Massachusetts	02215	—
Case Western Reserve University	Cleveland	Ohio	44106	—
Cleveland Clinic	Cleveland	Ohio	44195	—
University of Oklahoma	Oklahoma City	Oklahoma	73104	—
MD Anderson Cancer Center	Houston	Texas	77030	—
START	San Antonio	Texas	78229	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT03364400, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted May 15, 2023 · Synced Nov 15, 2026